APX001/SSS07 was discovered through the use of Apexigen‘s proprietary monoclonal antibody technologies and has been produced by 3SBio in China under a license from Apexigen. APX001/SSS07 is the second antibody uncovered through the use of Apexigen’s technologies that an IND offers been filed with the SFDA. ‘We congratulate our co-workers at 3SBio upon this IND filing,’ said Dr. Xiaodong Yang, President and CEO of Apexigen. ‘It represents the hard work of many individuals functioning collaboratively as a team to attain the common goal. We anticipate continuing success inside our collaboration.’.. 3SBio documents APX001 IND software with SFDA in China Apexigen, Inc., an emerging biopharmaceutical company focused on the discovery and development of monoclonal antibody therapeutics, announced today that it is partner, 3SBio [SSRX] of Shenyang, China, filed an Investigational New Drug software for APX001, also known as SSS07, with the State Meals and Drug Administration in China.It is in charge of releasing positively charged calcium ions from storage space compartments within cells, which combine with muscle proteins to trigger contraction then. In response to temperature, mutations in RYR1 cause excessive amounts of calcium to leak from the storage result in and compartment uncontrolled muscle tissue contractions. The united team found that AICAR decreases calcium leakage from RYR1, diminishing heat-induced contractions thus, muscle damage, and death. In another but related article published in the journal Anesthesiology, Dirksen and co-workers reported cases of two children with RYR1 mutations who died following episodes triggered by either a viral fever or contact with environmental heat stress.